| Higher Serum DPP-4 Enzyme Activity and Decreased Lymphocyte CD26 Expression in Type 1 Diabetes. | |
| | |
MedLine Citation:
|
PMID: 21785903 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Dipeptidyl peptidase-4 (DPP-4) is involved in the metabolism of peptide hormones, T-cell activation and proliferation. In type 1 diabetes mellitus (T1DM) β-cell destruction involves a number of dysregulated T-cells. Our aim was to assess the serum DPP-4 activity and the lymphocyte membrane bound CD26 expression in patients with type 1 diabetes and healthy controls. Ninety-eight (T1DM: 48, F/M = 20/28, mean age: 34.4y; control: 50, F/M = 39/11 mean age: 32,4y) individuals were included. Fasting serum DPP-4 enzymatic activity, plasma glucose (FPG), CD26 expression on CD3+, CD4+ and CD8+ lymphocytes, HbA1c and body mass index (BMI) were assessed. ICA and GAD antibodies were assessed in the T1DM group. DPP-4 enzymatic activity was determined by kinetic enzyme assay, ICA and GAD were assessed by ELISA. Determination of the CD26 expression on CD3+, CD4+ and CD8+ lymphocytes was performed by flow-cytometric analysis. We found higher serum DPP-4 activity (Mean: T1DM: 30.069 U/L, control: 22.62 U/L, p < 0.0001) and decreased CD26 lymphocyte expression on all lymphocyte subpopulations in T1DM. Fasting serum DPP-4 activity was independent from the ICA or GAD status of patients with T1DM. Here we first present that the serum DPP-4 activity is increased and the lymphocyte membrane bound CD26 expression is decreased in type 1 diabetes. Decreased lymphocyte membrane bound CD26 expression in T1DM might be a novel part of the T-lymphocyte regulatory dysfunction observed in type 1 diabetes mellitus. These results might provide some basis for the clinical implication of DPP-4 inhibition in patients with T1DM. |
| | |
Authors:
|
Tímea Varga; Anikó Somogyi; Gábor Barna; Barna Wichmann; Géza Nagy; Károly Rácz; László Selmeci; Gábor Firneisz |
Related Documents
:
|
12164523 - Charcot arthropathy of the diabetic foot. current concepts and review of 36 cases. 18713273 - Intracutaneous injection of the macrophage-activating lipopeptide-2 (malp-2) which acce... 20840193 - Ppar-γ agonism for cardiovascular and renal protection. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-7-22 |
Journal Detail:
|
Title: Pathology oncology research : POR Volume: - ISSN: 1532-2807 ISO Abbreviation: - Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-7-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9706087 Medline TA: Pathol Oncol Res Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary, timcsus@yahoo.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Can Lymphatic Vascular Density Be Used in Determining Metastatic Spreading Potential of Tumor in Inv...
Next Document: An efficient multiplex genotyping approach for detecting the major worldwide human Y-chromosome hapl...